Keynote 667

For patients ages 3-25 with newly diagnosed classical Hodgkin lymphoma

Safety and Efficacy of Pembrolizumab in Children and Young Adults With Classical Hodgkin Lymphoma

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational immunotherapy is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll in the trial will receive chemotherapy at the beginning of the study. Patients will be assessed after 2 cycles of chemotherapy to see how they respond to the treatment.

  • Patients that have an inadequate response to chemotherapy will receive study medication (pembrolizumab) in addition to continuing chemotherapy. Radiotherapy may or may not be an option.
  • Patients that have an adequate response to chemotherapy will not receive any further study treatment. Your study doctor will determine your next treatment per standard of care and will discuss this with you in more detail.


Trial Purpose
2

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03407144 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Stay Informed

Sign up to receive email alerts about this trial or when a location becomes available

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Hodgkin Lymphoma

Age range

3 — 25

Gender(s)

All

Trial Purpose

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

Sign up to receive an email alert when a clinical trial location in your area begins accepting patients.

    Location
    Status
  • Greenville, South Carolina, United States, 29607
    Recruiting
  • Detroit, Michigan, United States, 48201
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-667

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
keynote 667 trial logo

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.